Reuters - A heated three-year safety debate about a GlaxoSmithKline Plc diabetes pill reaches a climax this week as opponents and backers face off at a U.S. meeting that will help decide the drug's fate.
Source
الذين يشاهدون الموضوع الآن: 1 (0 من الأعضاء و 1 زائر)
ضوابط المشاركة
|
|
||
|
|
|
|
|
|
||
مواقع النشر (المفضلة)